United States Federal Circuit

Plaintiff's patent, concerning a method of screening for protein inhibitors or activators, was properly deemed invalid. Judgment of noninfringement is affirmed.

Appellate Information

• Decided 05/07/2004
• Published 05/07/2004

Judges

• Before MAYER, Chief Judge, NEWMAN and CLEVENGER, Circuit Judges.

Court

• United States Federal Circuit

Counsel

• For Appellant:
  
• R. Terrance Rader,Rader Fishman & Grauer PLLC, of Bloomfield, Michigan, argued for plaintiff-appellant Housey Pharmaceuticals, Inc.


• For Appellees:
  
• Herbert F. Schwartz, Fish & Neave, of New York, New York, for defendants-cross appellants AstraZeneca UK Ltd., et al.   With him on the brief were Denise L. Loring, and Frances M. Lynch., Also on the brief were John F. Lynch, Attorney of Record, Howrey Simon Arnold & White, LLP, of Houston, Texas, for defendant-cross appellant Merck & Co., Inc. With him on the brief were Richard L. Stanley, Nicholas G. Barzoukas, and James C. Pistorino.   Of counsel were Paul D. Matukaitis and Edward W. Murray, Merck & Co., Inc. of Rahway, New Jersey., Also on the brief was William F. Lee, Attorney of Record, Hale and Dorr LLP, of Boston, Massachusetts, who argued for defendants-appellants Wyeth and Wyeth Pharmaceuticals, Inc. With him on the brief was Lisa J. Pirozzolo., Also on the brief was Robert L. Baechtold, Attorney of Record for defendant-cross appellant Bristol-Myers Squibb Company, Fitzpatrick, Cella, Harper & Scinto, of New York, New York. With him on the brief were Scott K. Reed and Steven C. Kline.   Of counsel were Jack B. Blumenfeld, Karen Jacobs Louden, and Mary B. Graham, Morris, Nichols, Arsht & Tunnell, of Wilmington, Delaware.